The first assay for measurement of immunoreactive parathyroid hormone (iPTH) was described by Berson et al. in 1963 (1) , and this landmark paper signaled a new era in the evaluation of disorders of calcium homeostasis. In recent years, the PTH radioimmunoassay has become one of the most commonly ordered endocrine tests, largely because of its usefulness in the differential diagnosis of the causes of hypercalcemia.
Although there are considerable variations among different assays in sensitivity, specificity and clinical performance, at least some of them have served physicians reasonably well in their evaluation of hypercalcemic patients. It is now generally accepted that assays with high sensitivity and specificity for the biologically inert carboxyl (C)-terminal region of PTH will discriminate patients with primary hyperparathyroidism (10 HPT) from normal subjects or from patients with other causes of hypercalcemia better than assays specific for the biologically active amino (N) terminal region (2) .
The advantage of using an assay for the inactive region of PTH for the diagnosis of 1°HPT is probably related to the longer half life in the circulation of C-terminal fragments compared to N-terminal fragments and the intact PTH molecule (3); this difference in half lives results in predominance of C-terminal fragments in the circulation of 1°HPT patients (4) .
The value of iPTH measurement in patients with chronic renal failure (CRF) has been less apparent. Many investigators have noted that iPTH has usually been elevated in patients on chronic hemodialysis and that the values were frequently much higher than those in 1°HPT (5, 6) . However, variable increases in serum iPTH have been described in mild or moderate renal insufficiency. Reiss, et al. (7) reported elevated iPTH values in patients with glomerular filtration rates, (GFR) as high as 70-80 mil min and in one patient with a GFR of 109 ml/min, but Arnaud (8) found increased iPTH levels only when the GFR was below 40 ml/min. These variations have been attributed to differences in assay specificity (9) .
Nevertheless, it has generally been accepted that an increase in PTH secretion is one of the important early The International Journal Of Artificial Organs I Vol. 4 no. 3, 1981 I p.p. , © by Wichtig Editore srl, 1981 events in the progression of CRF (10) . Secondary hyperparathyroidism (2°HPT) has therefore been considered «an almost universal concomitant of renal failure of any degree, even without demonstrable renal osteodystrophy» (11) .
Because C-terminal iPTH assays have consistently shown elevated values in CRF patients, while N-terminal or intact iPTH assays have not, it has been concluded that only assays with C-terminal specificity will give appropriate clinical correlation (2, 12) . However, there has been considerable variation of C-terminal iPTH results and a lack of correlation with clinical improvement in renal osteodystrophy patients treated with 25-hydroxycholecalciferol (13) . Many of the patients who showed the best clinical improvement of their 2°HPT and renal osteodystrophy, as demonstrated by quantitative bone histomorphometry and biochemical and clinical evaluation, exhibited unaltered C-terminal iPTH levels many times the upper limit of normal. Because the most commonly available iPTH assay is the C-terminal type, many dialysis centers have not routinely employed iPTH measurements in evaluating or monitoring their patients.
The explanation for such inconsistent findings with C-terminal iPTH assays lies in the role of the kidney in the removal of C-terminal PTH fragments from the circulation. Arnaud, et al. (6) showed that CRF patients had significantly higher C-terminal iPTH values than patients with hypocalcemia and normal renal function, an observation largely unexplained at the time. Since, in the Bricker hypothesis (10), hypocalcemia is the cause of increased PTH secretion, these two groups of patients should have had similar iPTH values, but the grossly higher values in the CRF patients suggested that an additional factor was involved.
There is now conclusive evidence that the kidney is the primary site for the clearance of C-terminal PTH fragments. In CRF the half life for removal of circulating C-terminal fragments is prolonged by as much as 30 fold over the half life in 1°HPT (3). As much as 80% of the C-terminal iPTH measured in hemodialysis patients has been estimated to consist of accumulated (uncleared) fragments, while only 20% or less of the measured Cterminal iPTH represents recent glandular function (14) . Gel filtration studies have shown a higher proportion of C-terminal iPTH fragments in serum from CRF patients than in serum from patients with 1°HPT (15) . Thus, it is highly likely that renal insufficiency 1) causes accumulation of C-terminal PTH fragments to an extent that the degree of 2°HPT in CRF patients is significantly overestimated by C-terminal iPTH assays, and 2) prevents or impairs clearance of PTH immunoreactivity that might reflect improvement in a patient's clinical condition.
Recently, we described our experience in CRF with an iPTH assay that does not react appreciably with C-terminal PTH fragments, but rather with intact PTH and possibly with N-terminal PTH fragments (16) . The findings with this assay for intact iPTH differ considerably from the results typically described for C-terminal iPTH assays. Approximately 14% of 160 unselected CRF patients had normal intact iPTH values, and in the above mentioned renal osteodystrophy protocol, 5 of 16 patients tested had normal intact iPTH levels prior to treatment.
One interpretation of these data is that the patients with normal intact iPTH levels did have 2°HPT, but under the stimulus of decreased serum ionized calcium levels (the Bricker hypothesis), the increased secreted intact PTH was rapidly cleaved to active (and inactive) PTH fragments; thus the intact iPTH levels were inappropriately low. However, quantitative bone histomorphometric analyses of biopsies from 'the 36 patients in the above mentioned protocol showed that 12 patients had no bone evidence of 2°HPT (such as increased osteoclast counts and increased active osteoclastic resorption surface); they had only the characteristics of osteomalacia (increased osteoid surface and trabecular bone volume (17) . Only 16 of the 36 patients had intact iPTH measurements due to lack of adequate specimens. Four of five patients with normal intact iPTH levels were in this latter group of «inactive bone» patients, whereas 9 of the 11 patients with elevated intact iPTH values were in the former group of 2°HPT (<<active bone») patients.
The C-terminal iPTH levels in the 12 patients with inactive bone ranged from 3 to 17 times the upper limit of normal, but only two had values greater than 10 times normal. The mean C-terminal iPTH value was 7 times normal, a degree of overestimation similar to other reports (14) . On the other hand, the mean C-terminal iPTH value in the 24 patients with active bone was approximately 40 times the upper normal limit, the values ranging from 5 to 130 times normal. Only one patient had a value less than 11 times normal. The great disparity in C-terminal iPTH levels between these two groups suggests that modestly elevated C-terminal iPTH values 113 (i.e.. up to 10 times normal) may not be indicative of 2°H
PT in a dialysis patient, but are simply due to a lack of clearance of C-terminal fragments. Only when the C-terminal iPTH levels are greater than 10 times normal is there a high probability that the patient has 2°HPT. The reader should be cautioned that this degree of overestimation is probably variable among different C-terminal iPTH assays and should be evaluated for each assay.
If a C-terminal type of assay consistently overestimates the degree of 2°HPT, the obvious question is whether one should rely instead on an intact iPTH assay, or any PTH assay at all. The intact iPTH assay if used alone may occasionally give a normal result in a patient who does have 2°HPT, or an elevated result in a patient who does not have 2°HPT. Therefore, we believe the best procedure is to use both assays at least once on the same specimen and to compare the results for that patient with the results for other patients with similar GFR's. When used together and interpreted in light of the above discussion, the two assays provide a strong basis for evaluating a given patient.
The principal use of an iPTH assay in CRF patients is to periodically monitor responses to maintenance dialysis and therapeutic regimens. However, many dialysis centers have not been satisfied with the usefulness of iPTH measurements because the type of iPTH assay most commonly available (C-terminal iPTH) has shown inconsistent results and a failure to correlate with clinical improvement.
Our experience suggests that the intact iPTH assay may have greater utility in routine monitoring of dialysis patients (16) . Among the 24 patients with histomorphometric evidence of 2°HPT mentioned above, the intact iPTH assay showed a high correlation with clinical improvement as determined by biochemical measurements including serum alkaline phosphatase and calcium, and histomorphometric parameters including osteoclast counts and percentage of active resorption surface (17) . In several improved patients intact iPTH levels fell to within normal limits, frequently concurrent with the return of alkaline phosphatase to normal.
The C-terminal iPTH responses in individual 2°HPT patients were quite variable. Some patients with biochemical, histomorphometric, and clinical evidence of improvement had increased C-terminal iPTH levels. Some improved patients showed fluctuations in C-terminal iPTH, but no significant decrease, while others did show significant decreases. Among all improved patients, the mean C-terminal iPTH levels failed to correlate with any other parameters. In none of the patients in whom Cterminal iPTH decreased did the values fall to within normal limits; the greatest decreases were only to about 5-10 times the upper limit of normal (in other words, to about the same level by which the assay overestimates 2°HPT). The reason for the wide variations in C-terminal iPTH responses is not known, but could be due to differences among patients in residual renal function, the degree of hepatic involvement, since the liver is also a known site of PTH metabolism (18) , or other factors.
The correlation of intact iPTH with clinical improvement has an obvious basis. Intact iPTH measurement provides a direct assessment of acute parathyroid gland function since the major secreted form of the hormone is intact PTH (4) . The disappearance of intact iPTH from the peripheral circulation is only modestly prolonged with renal impairment (3), because its rate of disappearance is primarily dependent on liver function (18) .
Even though the intact iPTH assay showed a better correlation with clinical improvement, we believe this assay should be used along with the C-terminal iPTH assay rather than instead of it. A CRF patient who has shown significant clinical improvement along with a fall in intact iPTH to normal levels may still have parathyroid hyperplasia and be continuing to secrete inactive C-terminal PTH fragments-perhaps resulting from intra-glandular degradation of stored intact PTH as a mechanism of eliminating these vast glandular stores of intact hormone (Arnaud, C.D., personal communication). It is thought that the very high C-terminal iPTH levels that persist long after intact iPTH has fallen to normal reflect the enlarged size of the glands, and only when C-terminal iPTH levels have fallen to about 10 times normal (depending on the particular assay) might it be assumed that the hyperplastic glands have shrunk to their normal size. Thus, the return of intact iPTH levels to normal should not be interpreted as indicating that the patient's response to therapy is complete, unless C-terminal iPTH has also been reduced as described. If the therapy that led to reduction of intact iPTH is stopped too early, the hyperplastic parathyroid glands may release large quantities of intact PTH leading to a worsening of the patient's condition.
There have been several recent therapeutic advances in treatment of uremia. New vitamin 0 metabolites have become available for the therapy of renal osteodystrophy and hypocalcemia. Cimetidine (19) and propranolol (20) have been shown to lower iPTH levels in some CRF patients. In each case, the authors concluded that the action of the respective drug was on PTH secretion, because the assay employed in each study measured both intact PTH and C-terminal fragments. However, since peripheral serum in CRF patients contains predominantly C-terminal fragments, the large decreases in iPTH most likely reflected decreases in C-terminal fragments. Use of an as-say which measures intact PTH, but does not measure C-terminal fragments will be necessary to determine whether these drugs actually reduce PTH secretion. The improvements in CRF patient treatment made possible by these new medications and other therapies will be enhanced by the availability of more selective and sensitive iPTH assays.
